Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2024-04-16 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
2023年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023年度内部控制自我评价报告' which translates to '2023 Annual Internal Control Self-Evaluation Report'. It discusses the company's internal control evaluation for the year ending December 31, 2023, including detailed descriptions of internal control environment, control activities, and evaluation conclusions. The document is comprehensive and contains substantive content about internal control effectiveness, defect recognition, and remediation. It is not a brief announcement or a certification letter but a full report on internal control self-assessment. This type of document aligns with an Audit Report / Information (AR) category, as it focuses on internal control evaluation and related audit matters rather than a full annual report or other categories. The document length (6163 characters) supports it being a full report rather than a short announcement. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-16 Chinese
独立董事提名人声明与承诺
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of Chengdu Oukang Pharmaceutical Co., Ltd. nominating candidates for independent directors. It includes detailed statements and commitments regarding the qualifications, independence, and compliance of the nominees with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management changes, specifically the nomination of independent directors. The document length is 2500 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Board/Management Information (MANG).
2024-04-16 Chinese
第三届监事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 21st meeting of the third Supervisory Board of Chengdu Oukang Pharmaceutical Co., Ltd. It includes multiple agenda items such as approval of the 2023 annual report, financial statements, budget, dividend distribution plan, appointment of auditors, related party transactions, internal control reports, and supervisory board elections. The document references various reports and announcements that have been or will be disclosed separately on the Beijing Stock Exchange information platform, indicating that this document itself is a formal meeting resolution announcement rather than the reports themselves. The document is comprehensive and contains substantive content about board decisions and approvals, which aligns with the category of Board/Management Information (MANG). It is not a full annual report (10-K), audit report (AR), or a simple announcement of report publication (RPA). Therefore, the best classification is MANG with high confidence.
2024-04-16 Chinese
2023年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled '2023年度会计师事务所履职情况评估报告' which translates to '2023 Annual Evaluation Report on the Performance of the Accounting Firm'. It discusses the appointment and evaluation of the auditing firm for the company's 2023 annual audit. The content includes details about the auditing firm, their qualifications, the audit process, and the company's assessment of the auditor's performance. It does not contain the full annual report or financial statements but is an evaluation related to the audit process. The document length is short (1446 characters) and it is a standalone report about the audit firm's performance, not the audit report itself or the annual report. This fits the definition of an Audit Report / Information (AR) which includes standalone audit reports and related evaluations, excluding full annual reports. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-16 Chinese
成都欧康医药股份有限公司年度募集资金存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "年度募集资金存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Deposit and Use of Raised Funds." It includes detailed information about the company's fundraising activities, the amount of funds raised, their usage, and compliance with regulatory requirements. The report is prepared by a registered accounting firm providing an attestation on the management's report about the use of raised funds for the year 2023. The document references specific regulatory guidelines related to fundraising management and includes financial figures and usage details. This type of report is a specialized audit or attestation report focusing on the use of capital raised by the company, rather than a full annual report or earnings release. It is not a simple announcement or a proxy statement but a standalone audit-related verification report. Therefore, the most appropriate classification is Audit Report / Information (AR). The document length (over 14,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification letter.
2024-04-16 Chinese
2023年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is a 2023 annual performance forecast announcement by Chengdu Oukang Pharmaceutical Co., Ltd. It provides preliminary financial data for the full year 2023, including expected net profit and reasons for profit decline. The data is unaudited and explicitly states that the final audited figures will be disclosed in the 2023 annual report. The document is short (1239 characters) and serves as a performance forecast rather than a full annual report. It does not contain full financial statements or comprehensive analysis, but rather a summary of expected results and risk warnings. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of periodic financial results with key highlights only. FY 2023
2024-02-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.